Brief: Sab Biotherapeutics Provides Company Update For Q3 2022 Financial Results
15/11/2022 14:06
Nov 15 (Reuters) - SAB Biotherapeutics Inc SABS.O :
* SAB BIOTHERAPEUTICS PROVIDES COMPANY UPDATE FOR Q3 2022
FINANCIAL RESULTS
* SAB BIOTHERAPEUTICS INC - QTRLY LOSS PER SHARE $0.16
* SAB BIOTHERAPEUTICS - REAFFIRMS EXISTING CASH RUNWAY WILL
BE
ENOUGH TO FUND OPERATING EXPENSES, CAPEX REQUIREMENTS THROUGH
JULY 2023
Source text for Eikon: ID:nGNXc2g8yZ
Further company coverage: SABS.O
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies